VMS Industry Wants Into CBD Market, Plus Enforcement On Firms Already There
Executive Summary
FDA policy change making hemp and CBD eligible for use a dietary ingredients should include requiring regulatory compliance by companies already marketing products with the ingredients, representatives of firms and industry trade groups said at public hearing. Requirements include submitting to FDA pre-market notifications of proof of a reasonable expectation safety for an ingredient's intended use. "Ensure the rule of law is upheld by barring any company illegally marketing CBD or hemp-derived dietary ingredients from submitting an NDI for the period of time that their products have been illegally marketed," says NOW Health exec Aaron Secrist.
You may also be interested in...
BioMedican Pitches Cannabinoid Biosynthesis Investing; Cultivated Market Sprouts More Deals
BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.
Legislating Hemp As Dietary Ingredient: Wrapping US Market In A Bow, Or Tying DSHEA In Knots?
House legislation to exempt hemp-derived cannabinoids from FDA rule that an “article” previously studied or approved for use as drugs is not allowed for use in dietary supplements either resolves a conundrum or raises additional questions for the agency and the industry.
Congress Ready To Propose Legislation To Deliver US FDA’s Wish: Allowing CBD Use In Supplements
House Energy and Commerce members are expected soon to introduce a bill to make lawful the use of CBD and other hemp-derived ingredients, other than THC, in dietary supplements. Capitol Hill interest in proposing legislation, says Sen. Wyden , will grow if FDA doesn’t bring some order to the CBD space.